| Identification | Back Directory | [Name]
Benzoic acid, 3-[4-[[[3,4-dihydro-6-methyl-4-oxo-3-(phenylmethyl)-2-quinazolinyl]thio]methyl]-1H-1,2,3-triazol-1-yl]- | [CAS]
2446055-29-2 | [Synonyms]
HSP90-IN-13 Benzoic acid, 3-[4-[[[3,4-dihydro-6-methyl-4-oxo-3-(phenylmethyl)-2-quinazolinyl]thio]methyl]-1H-1,2,3-triazol-1-yl]- | [Molecular Formula]
C26H21N5O3S | [MOL File]
2446055-29-2.mol | [Molecular Weight]
483.54 |
| Hazard Information | Back Directory | [Uses]
HSP90-IN-13 (compound 5k) is a highly potent HSP90 pan inhibitor with an IC50 value of 25.07 nM. HSP90-IN-13 has multi-target activity against EGFR, VEGFR-2 and Topoisomerase-2. HSP90-IN-13 causes cell cycle arrest at G2/M phase and induces apoptosis of MCF-7 cells through mitochondrial-mediated pathway[1]. | [IC 50]
HSP90: 25.07 nM (IC50); Topoisomerase-2: 25.85 nM (IC50); EGFR: 38.5 nM (IC50); VEGFR-2: 126.95 nM (IC50) | [References]
[1] El-Shafey HW, et al. Synthetic approaches, anticancer potential, HSP90 inhibition, multitarget evaluation, molecular modeling and apoptosis mechanistic study of thioquinazolinone skeleton: Promising antibreast cancer agent. Bioorg Chem. 2020 Aug;101:10398 DOI:10.1016/j.bioorg.2020.103987 |
|
|